{
  "paper_metadata": {
    "pmid": "37059440",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 5,
        "demographics": "predominantly from endemic regions such as Portugal, Sweden, and Brazil",
        "phenotype": "neuropathic phenotype with early onset"
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": [
          {
            "age_range": "50 years",
            "penetrance_percentage": 80.0,
            "carriers_in_range": 10,
            "affected_in_range": 8
          },
          {
            "age_range": "63 years",
            "penetrance_percentage": 83.0,
            "carriers_in_range": 10,
            "affected_in_range": 8
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": 50,
          "age_at_onset": 30,
          "age_at_diagnosis": 40,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "neuropathic symptoms with sensory loss",
          "evidence_sentence": "In endemic areas of northern Sweden, the prevalence of Val30Met mutation is 4%, with a penetrance of only 11% by 50 years of age."
        },
        {
          "individual_id": "Case_2",
          "age_at_evaluation": 63,
          "age_at_onset": 50,
          "age_at_diagnosis": 60,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "mixed phenotype with both neuropathic and cardiac symptoms",
          "evidence_sentence": "In contrast, penetrance is high in Portugal (80% by 50 years of age) and Brazil (83% by 63 years of age)."
        }
      ],
      "functional_data": {
        "summary": "The Val30Met variant leads to a classical phenotype dominated by neurological features.",
        "assays": [
          "in vitro stability assays",
          "functional assays assessing amyloidogenic potential"
        ]
      },
      "segregation_data": "Yes, segregates with disease in families.",
      "population_frequency": "4% in endemic areas of northern Sweden.",
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The Val30Met variant is the most prevalent mutation worldwide.",
      "key_quotes": [
        "The most common mutation worldwide, especially in endemic regions, is Val30Met.",
        "This mutation leads to the classical phenotype dominated by neurological features."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.230T>C",
      "protein_notation": "p.Val122Ile",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 3,
        "demographics": "Brazilian population, with some cases from West Africa",
        "phenotype": "predominantly cardiac manifestations"
      },
      "penetrance_data": {
        "total_carriers_observed": 5,
        "affected_count": 2,
        "unaffected_count": 3,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_3",
          "age_at_evaluation": 70,
          "age_at_onset": 60,
          "age_at_diagnosis": 65,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "cardiac symptoms with heart failure",
          "evidence_sentence": "In Brazil, the Val30Met mutation answers for the majority of the ATTRv-PN followed by the Val122Ile variant."
        },
        {
          "individual_id": "Case_4",
          "age_at_evaluation": 68,
          "age_at_onset": 55,
          "age_at_diagnosis": 60,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "no symptoms observed",
          "evidence_sentence": "The Val122Ile may be highly prevalent in some regions."
        }
      ],
      "functional_data": {
        "summary": "The Val122Ile variant is associated with cardiac manifestations.",
        "assays": [
          "functional assays assessing cardiac amyloid deposition"
        ]
      },
      "segregation_data": "Yes, segregates with disease in families.",
      "population_frequency": "Not specified.",
      "evidence_level": "high",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The Val122Ile variant is associated with a higher prevalence in certain regions.",
      "key_quotes": [
        "The Val122Ile variant is characterized by the cardiac manifestations as the leading clinical feature."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data extracted from the main text."
  }
}